Influence of the LILRA3 Deletion on Multiple Sclerosis Risk: Original Data and Meta-Analysis.

Ortiz, Miguel A.; Núñez, Concepción; Ordóñez, David; Álvarez Cermeño, Jose Carlos; Martínez Rodríguez, José Enrique; Sánchez, Antonio J.; Arroyo, Rafael; Izquierdo, Guillermo; Malhotra, Sunny, 1984-; Montalbán Gairín, Xavier; García Merino, Antonio; Munteis Olivas, Elvira; Alcina, Antonio; Comabella López, Manuel; Matesanz, Fuencisla; Villar, Luisa Maria; Urcelay, Elena

doi:http://dx.doi.org/10.1371/journal.pone.0134414

Influence of the LILRA3 Deletion on Multiple Sclerosis Risk: Original Data and Meta-Analysis.

Citation

Ortiz MA, Núñez C, Ordóñez D, Alvarez-Cermeño JC, Martínez-Rodriguez JE, Sánchez AJ. et al. Influence of the LILRA3 Deletion on Multiple Sclerosis Risk: Original Data and Meta-Analysis. PLoS One. 2015 Aug 14;10(8):e0134414. doi: 10.1371/journal.pone.0134414.

Abstract

BACKGROUND: Multiple sclerosis (MS) is a neurodegenerative, autoimmune disease of the central nervous system. Genome-wide association studies (GWAS) have identified over hundred polymorphisms with modest individual effects in MS susceptibility and they have confirmed the main individual effect of the Major Histocompatibility Complex. Additional risk loci with immunologically relevant genes were found significantly overrepresented. Nonetheless, it is accepted that most of the genetic architecture underlying susceptibility to the disease remains to be defined. Candidate association studies of the leukocyte immunoglobulin-like receptor LILRA3 gene in MS have been repeatedly reported with inconsistent results. OBJECTIVES: In an attempt to shed some light on these controversial findings, a combined analysis was performed including the previously published datasets and three newly genotyped cohorts. Both wild-type and deleted LILRA3 alleles were discriminated in a single-tube PCR amplification and the resulting products were visualized by their different electrophoretic mobilities. RESULTS AND CONCLUSION: Overall, this meta-analysis involved 3200 MS patients and 3069 matched healthy controls and it did not evidence significant association of the LILRA3 deletion [carriers of LILRA3 deletion: p = 0.25, OR (95% CI) = 1.07 (0.95-1.19)], even after stratification by gender and the HLA-DRB1*15:01 risk allele.